Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer

References

• von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: Facts and numbers. J Cachexia Sarcopenia Muscle 2010;1:1–5.
   PubMed Web of Science ®Google Scholar
• Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: A new definition. Clin Nutr 2008;27:793–9.
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 2011;12:489–95.
   PubMed Web of Science ®Google Scholar
• Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in patients with non-small cell lung cancer: A contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 2010;91:1133S–7S.
   PubMed Web of Science ®Google Scholar
• Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013;31:1539–47.
   PubMed Web of Science ®Google Scholar
• Parsons HA, Baracos VE, Dhillon N, Hong DS, Kurzrock R. Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One 2012;7:e29330.
   PubMed Web of Science ®Google Scholar
• Prado CM, Sawyer MB, Ghosh S, Lieffers JR, Esfandiari N, Antoun S, et al. Central tenet of cancer cachexia therapy: Do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr [Internet]. [cited 2013 Aug 21]. Available from: http://ajcn.nutrition.org/content/98/4/1012.full.pdf.
   Google Scholar
• Antoun S, Borget I, Lanoy E. Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Curr Opin Support Palliat Care 2013;7:383–9.
   PubMed Web of Science ®Google Scholar
• Baracos V, Caserotti P, Earthman CP, Fields D, Gallagher D, Hall KD, et al. Advances in the science and application of body composition measurement. J Parenter Enteral Nutr 2012;36:96–107.
   PubMed Web of Science ®Google Scholar
• Murphy RA, Mourtzakis M, Chu QS, Reiman T, Mazurak VC. Skeletal muscle depletion is associated with reduced plasma (n-3) fatty acids in non-small cell lung cancer patients. J Nutr 2010;140:1602–6.
   PubMed Web of Science ®Google Scholar
• Dalal S, Hui D, Bidaut L, Lem K, Del Fabbro E, Crane C, et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: A pilot study. J Pain Symptom Manage 2012;44:181–91.
   PubMed Web of Science ®Google Scholar
• Di Sebastiano KM, Yang L, Zbuk K, Wong RK, Chow T, Koff D, et al. Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: The relationship with diabetes and anaemia. Br J Nutr 2013;109 :302–12.
   PubMed Web of Science ®Google Scholar
• Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009;15:6973–9.
   PubMed Web of Science ®Google Scholar
• Lieffers JR, Mourtzakis M, Hall KD, McCargar LJ, Prado CM, Baracos VE. A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: Contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr 2009;89:1173–9.
   PubMed Web of Science ®Google Scholar
• Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002;87:264–7.
   PubMed Web of Science ®Google Scholar
• Mannion E, Gilmartin JJ, Donnellan P, Keane M, Waldron D. Effect of chemotherapy on quality of life in patients with non-small cell lung cancer. Support Care Cancer 2014;22:1417–28.
   PubMed Web of Science ®Google Scholar
• Gronberg BH, Sørhaug S, Hjelde HH, Stene GB, Amundsen T, editor. Variation in health-related quality of life (HRQoL) during chemotherapy for advanced non- small cell lung cancer. 2013 ASCO Annual Meeting; 2013; Chicago, Illinois, USA. J Clin Oncol 2013;31 (Suppl; abstr 9562).
   Google Scholar
• Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 2009;3:269–75.
   PubMedGoogle Scholar
• Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008;33:997–1006.
   PubMed Web of Science ®Google Scholar
• Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: Estimation from a single abdominal cross-sectional image. J Appl Physiol 2004;97:2333–8.
   PubMed Web of Science ®Google Scholar
• Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol 2008;9:629–35.
   PubMed Web of Science ®Google Scholar
• Sobin LHG, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours, 7th ed. Wiley-Blackwell; Oxford. 2009.
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176–81.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality- of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76.
   PubMed Web of Science ®Google Scholar
• Gronberg BH, Sundstrom S, Kaasa S, Bremnes RM, Flotten O, Amundsen T, et al. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer 2010;46:2225–34.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285–91.
   PubMed Web of Science ®Google Scholar